Market accessCompany release

Abeona's Zevaskyn sales reach $13.5M in Q3 as NTAP status takes effect

🇺🇸 Abeona Therapeutics Inc. (ABEO) · Mon 09 Nov 2026

The gene-therapy maker reported 15 patients treated since launch, an eight-site QTC network and one batch that failed its identity assay release criterion.

Abeona Therapeutics reported third-quarter 2026 results on 9 November. Net revenue from Zevaskyn (prademagene zamikeracel), its therapy for recessive dystrophic epidermolysis bullosa, was $13.5 million. The company's headline put the rise at 18%.

Fifteen patients have been treated since launch. The company's QTC network has grown to eight sites. The summary available to us does not give the comparison period for the 18% rise or the full breakdown of treatments in the quarter.

The US Centers for Medicare & Medicaid Services' New Technology Add-On Payment (NTAP) status for Zevaskyn became effective on 1 October 2026. As context, NTAP is a Medicare mechanism that can provide extra payment to hospitals for costly new technologies used in inpatient care.

On the quality side, Abeona did not recognise revenue for one treatment after a batch failed the identity assay release criterion. The available information does not say what caused the failure or how the affected patient was managed.

Abeona also disclosed the acquisition of ABO-801, a programme for eosinophilic oesophagitis (EoE), and a $30 million PIPE (private investment in public equity) financing. No further terms were available to us.

What it means for your team

  • Market access: NTAP status effective from 1 October 2026 may affect hospital reimbursement conversations for Zevaskyn, though the practical impact will depend on site-level billing.
  • Quality: a batch failing an identity assay release criterion shows how release testing can directly affect revenue and patient supply for autologous cell and gene therapies.
  • Commercial rollout: the eight-site QTC network and 15 treated patients indicate the early pace of capacity-limited uptake for this therapy.

Company's press release (SEC filing): Abeona Therapeutics Inc. ↗

Article written by VigiEye from the official source (Abeona Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →